FDA's Response to COVID-19 Vaccine-Related Deaths in Children: A Call for Reflection and Change
The Food and Drug Administration's (FDA) second-highest official emphasized the need for reflection, humility, and change within the agency in response to a report suggesting that ten children may have died as a result of the COVID-19 vaccine. The FDA Chief Medical Officer highlighted the importance of acknowledging these deaths and raised concerns about the impact of vaccine mandates on young children. The delay in addressing these deaths and the cultural and systemic issues within the agency were also brought to light.
The FDA conducted an analysis of reports on suspected COVID vaccine-related deaths in children, with findings indicating that ten deaths were likely, probable, or possible outcomes of the vaccine. The process of reporting to the Vaccine Adverse Event Reporting System (VAERS) was described as tedious, leading to a potential underestimation of the actual number of deaths. The FDA's enforcement of safety studies by vaccine manufacturers was also questioned.
The official stressed the importance of maintaining high standards in vaccine approval and not compromising safety for the sake of profit. The significant financial gains from COVID-19 vaccines and the lack of generic competition were highlighted as factors that could influence decision-making within the agency. The need to prioritize patient safety and uphold rigorous standards in vaccine approval processes was emphasized.
In conclusion, the call for introspection and transformation within the FDA underscores the importance of prioritizing safety and transparency in vaccine approval processes. The acknowledgment of vaccine-related deaths in children and the need for a thorough evaluation of safety data reflect a commitment to ensuring the well-being of the public. The FDA's role in safeguarding public health and maintaining trust in vaccine efficacy and safety remains paramount.